Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People whose daily functioning is not severely limited by their illness (based on a standard scoring system called ECOG, with scores ranging from 0 to 2)
- People who have a confirmed diagnosis of a type of blood cancer called CML (Chronic Myeloid Leukaemia) in its chronic phase, with a specific genetic marker called BCR-ABL1
- People who have already tried at least one targeted cancer medicine (called a TKI) and whose treatment either stopped working, did not work well enough, or caused side effects they could not tolerate
- People who have previously been treated with a medicine called asciminib are also eligible
- People whose liver, kidneys, and other organs are functioning at an adequate level, as determined by local lab tests
Who may not be able to join:
- People who have received cancer-fighting treatments — including targeted therapy, interferon-alfa, antibody treatments, or chemotherapy — within 7 days before the first dose of the trial medicine
- People who have finished previous cancer treatment but still have ongoing side effects that have not improved to a mild level (confirm with trial site for exact grading details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 650-525-5535
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1 - Incidence of Dose Limiting Toxicities during the first cycle of treatment; Part 1 - Serious Adverse Events; Part 1 - Adverse Events; Part 2- Complete Hematologic Response (CHR); Part 2: Molecular response (MR); Part 2 - Best categorical shift in BCR-ABL1 transcript levels from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.